Anglo-Swedish pharmaceutical giant AstraZeneca reported a 2% increase in second-quarter net profit to $2.51 billion (€2.2 billion), beating analyst expectations and lifting its share price in early European trading on Monday. The Cambridge-based company reaffirmed its full-year outlook, driven by robust sales of its cancer medicines.
Total revenue rose 5% at constant exchange rates to $15.38 billion (€13.49 billion) in the three months ending June 30, with growth led by oncology and rare disease treatments. Core earnings per share reached $2.63, up 18% at constant exchange rates and above the consensus forecast of $2.48.
Pipeline confidence despite setback
CEO Pascal Soriot said the company remains "on track" to achieve its ambition of $80 billion (€70.15 billion) in total revenue by 2030. This confidence comes despite an unexpected late-stage trial failure earlier this month for the drug Wainua, which caused a temporary slump in AstraZeneca's shares. "We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months," Soriot said on Monday.
Shares rose 1.4% in early trading on European exchanges, recovering some ground after the July decline. The setback with Wainua is a rare misstep for a company that has built a reputation for consistent pipeline delivery.
Alongside its blockbuster cancer portfolio, AstraZeneca is investing in treatments for obesity, a rapidly growing market. Results released in June showed that patients taking the highest dose of its experimental weight-loss pill, elecoglipron, lost an average of 10.5% of their body weight after 26 weeks, with weight loss reaching 11.8% after 36 weeks.
The company's performance comes amid broader shifts in European pharmaceutical regulation and investment. As European policymakers focus on cutting energy waste and boosting industrial competitiveness, drugmakers like AstraZeneca are navigating complex market dynamics across the continent.
AstraZeneca's results also highlight the resilience of European pharma companies in a global environment where geopolitical tensions are disrupting other sectors. The company's strong cash generation and pipeline depth position it well for continued investment in research and development across its European operations.
Analysts noted that the beat on earnings per share was particularly encouraging, reflecting underlying profitability improvements. The company's focus on high-margin cancer drugs and rare disease therapies is paying off, even as it expands into new therapeutic areas like obesity.
AstraZeneca's performance also underscores the importance of the UK and Sweden as hubs for pharmaceutical innovation. The company maintains significant operations in both countries, contributing to Europe's broader life sciences ecosystem.
